Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases

杜兰大学 COBRE 用于心脏代谢疾病的临床和转化研究

基本信息

批准号：
10713994
负责人：
Jiang He
金额：
$ 37.29万
依托单位：
TULANE UNIVERSITY OF LOUISIANA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-03-10 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10713994
关键词：
3-Dimensional Address Adipose tissue Adult Amylases Apolipoproteins Bioinformatics Biostatistics Core Black race Blood Pressure Carbohydrates Cardiometabolic Disease Cardiovascular Diseases Cause of Death Centers of Research Excellence Cessation of life Chronic Kidney Failure Chronic Kidney Insufficiency Clinic Clinical Clinical Research Clinical Sciences Cohort Studies Collaborations Communities Copy Number Polymorphism Core Facility Data Deceleration Detection Diabetes Mellitus Diagnostic Disease Progression Ethnic Origin Faculty Financial Support Fostering Funding Funding Agency Gene Dosage Generations Grant Guidelines Health Health Policy Heart Hyperglycemia Hypertension Individual Intake Interdisciplinary Study Kidney Diseases Knowledge Leadership Louisiana Mediating Mentorship Metabolic Methodology Molecular Non-Insulin-Dependent Diabetes Mellitus Obesity Paper Participant Patient Care Peer Review Phase Pilot Projects Play Population Positioning Attribute Potassium Productivity Program Development Public Health Publishing Randomized Randomized, Controlled Trials Research Research Infrastructure Research Peer Review Research Personnel Research Project Grants Research Support Risk Factors Role Scientist Socioeconomic Status Supplementation Teacher Professional Development Testing Training Translational Research United States National Institutes of Health Universities biomarker identification black patient clinical center clinical practice community engagement cost diabetes risk disease disparity disorder prevention double-blind placebo controlled trial evidence base extracellular vesicles genetic variant health disparity improved innovation interdisciplinary collaboration member metabolomics mortality multidisciplinary next generation novel obese person peer programs racial disparity recruit response risk variant square foot success tenure track translational scientist

项目摘要

PROJECT SUMMARY/ABSTRACT (Overall) Cardiometabolic diseases are the leading cause of death in the US and have a disproportionate impact on the residents of Louisiana. During COBRE Phase 1, we have established the Tulane University Translational Science Institute (TUTSI), developed a critical mass of clinical and translational researchers, and increased scientific productivity in cardiometabolic diseases at Tulane University. Seven of 12 COBRE Research Project Leaders (RPLs) and Pilot Project Leaders (PPLs) have been funded for one or more peer-reviewed research projects from NIH and NSF. COBRE investigators have published 310 peer-reviewed scientific articles (140 from RPLs and PPLs and 170 from other COBRE investigators and collaborators) supported by the COBRE Phase 1 grant (GM109036). The overall objective of this COBRE Phase 2 application is to further develop and strengthen the clinical and translational research infrastructure at Tulane University and to continuously expand and support a critical mass of investigators with expertise in clinical and translational research in cardiometabolic diseases. The specific aims of this COBRE Phase 2 application are: 1) to enhance and sustain TUTSI, a university-wide thematic multidisciplinary Center for clinical and translational research on cardiometabolic diseases that motivates and facilitates interdisciplinary collaboration among basic, clinical, and population scientists; 2) to develop and nurture the next generation of investigators in clinical and translational science focused on cardiometabolic diseases; 3) to achieve the aims of the innovative Research Projects proposed by our four RPLs, including to elucidate metabolomic mechanisms of apolipoprotein L1 risk alleles associated with kidney disease progression in Black patients, to identify biomarkers of type 2 diabetes in adipose tissue-derived extracellular vesicles, to investigate the interrelations among amylase gene copy number variants, carbohydrate intake, and incident hyperglycemia and type 2 diabetes, and to test the intake-response effect of potassium supplementation on blood pressure in a randomized controlled trial; and 4) to establish and strengthen a Clinical Research and Community Engagement Core, Bioinformatics and Biostatistics Core, and Molecular Detection and Diagnostics Core and expand innovative technical and methodologic support to RPLs, PPLs, other COBRE investigators, and collaborators at Tulane University. Our COBRE program is unique because it addresses a significant public health problem in Louisiana and the nation and focuses on novel clinical and translational research. If funded, this COBRE Phase 2 program will play a central role in expanding and strengthening clinical and translational research infrastructure and in recruiting, nurturing, and advancing a cadre of well-trained interdisciplinary investigators in cardiometabolic disease research. The COBRE investigators will generate and apply new knowledge to patient care and disease prevention and ultimately contribute to reducing the burden of cardiometabolic diseases and improving the health of individuals and the public in Louisiana and beyond.

项目摘要/摘要（总体）心脏代谢疾病是美国的首要死因，对美国人的健康有着不成比例的影响。路易斯安那州居民。在 COBRE 第一阶段期间，我们建立了杜兰大学转化中心科学研究所（TUTSI）培养了一批临床和转化研究人员，并增加了杜兰大学在心脏代谢疾病方面的科学生产力。 12 个 COBRE 研究项目中的 7 个领导者 (RPL) 和试点项目领导者 (PPL) 已获得一项或多项同行评审研究的资助 NIH 和 NSF 的项目。 COBRE 研究人员已发表 310 篇经过同行评审的科学文章（140 来自 RPL 和 PPL 以及来自其他 COBRE 研究人员和合作者的 170 名）由 COBRE 支持第一阶段拨款（GM109036）。 COBRE 第 2 阶段应用的总体目标是进一步发展和加强杜兰大学的临床和转化研究基础设施不断扩大和支持大量具有临床和临床专业知识的研究人员心脏代谢疾病的转化研究。 COBRE 第 2 阶段应用程序的具体目标是： 1) 加强和维持 TUTSI，这是一个全校范围的临床和多学科主题中心促进和促进跨学科合作的心脏代谢疾病转化研究基础科学家、临床科学家和人口科学家； 2）培养和培养下一代研究者专注于心脏代谢疾病的临床和转化科学； 3）实现目标我们的四个 RPL 提出的创新研究项目，包括阐明代谢组学机制载脂蛋白 L1 风险等位基因与黑人患者肾脏疾病进展相关，以确定脂肪组织来源的细胞外囊泡中 2 型糖尿病的生物标志物，以研究相互关系淀粉酶基因拷贝数变异、碳水化合物摄入量、高血糖事件和 2 型之间的关系糖尿病，并测试补充钾对血压的摄入反应效果随机对照试验； 4) 建立和加强临床研究和社区参与核心、生物信息学和生物统计学核心、分子检测和诊断核心和扩大对 RPL、PPL、其他 COBRE 研究人员的创新技术和方法支持，以及杜兰大学的合作者。我们的 COBRE 计划是独一无二的，因为它面向重要的公众路易斯安那州和全国的健康问题，重点关注新颖的临床和转化研究。如果有资助，该 COBRE 第 2 期计划将在扩大和加强临床和转化方面发挥核心作用研究基础设施以及招募、培养和提升训练有素的跨学科骨干队伍心脏代谢疾病研究的研究者。 COBRE 调查人员将生成并应用新的患者护理和疾病预防知识，最终有助于减轻患者的负担心脏代谢疾病并改善路易斯安那州及其他地区个人和公众的健康。

项目成果

期刊论文数量（114）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The association of angiogenic factors and chronic kidney disease.

DOI：
10.1186/s12882-018-0909-2
发表时间：
2018-05-21
期刊：
BMC nephrology
影响因子：
2.3
作者：
Anderson CE;Hamm LL;Batuman G;Kumbala DR;Chen CS;Kallu SG;Siriki R;Gadde S;Kleinpeter MA;Krane NK;Simon EE;He J;Chen J
通讯作者：
Chen J

Blood pressure reduction in acute ischemic stroke according to time to treatment: a subgroup analysis of the China Antihypertensive Trial in Acute Ischemic Stroke trial.

DOI：
10.1097/hjh.0000000000001288
发表时间：
2017-06
期刊：
Journal of hypertension
影响因子：
4.9
作者：
Xu T;Zhang Y;Bu X;Wang D;Sun Y;Chen CS;Wang J;Peng H;Ju Z;Peng Y;Xu T;Li Q;Geng D;Zhang J;Li D;Zhang F;Guo L;Wang X;Cui Y;Li Y;Ma D;Zhang D;Yang G;Gao Y;Yuan X;Chen J;He J;CATIS investigators
通讯作者：
CATIS investigators

Associations of the Serum/Glucocorticoid Regulated Kinase Genes With BP Changes and Hypertension Incidence: The Gensalt Study.

血清/糖皮质激素调节激酶基因与血压变化和高血压发病率的关联：Gensalt 研究。

DOI：
10.1093/ajh/hpw122
发表时间：
2017
期刊：
American journal of hypertension
影响因子：
3.2
作者：
Zhang,Dingding;Gu,Dongfeng;He,Jiang;Hixson,JamesE;Rao,DabeeruC;Li,Changwei;He,Hua;Chen,Jichun;Huang,Jianfeng;Chen,Jing;Rice,TrevaK;Chen,Shufeng;Kelly,TanikaN
通讯作者：
Kelly,TanikaN

High Blood Pressure and Cardiovascular Disease.

DOI：
10.1161/hypertensionaha.119.14240
发表时间：
2020-02
期刊：
HYPERTENSION
影响因子：
8.3
作者：
Fuchs, Flavio D.;Whelton, Paul K.
通讯作者：
Whelton, Paul K.

Serum Matrix Metalloproteinase-9 and Cognitive Impairment After Acute Ischemic Stroke.

DOI：
10.1161/jaha.117.007776
发表时间：
2018-01-06
期刊：
Journal of the American Heart Association
影响因子：
5.4
作者：
Zhong C;Bu X;Xu T;Guo L;Wang X;Zhang J;Cui Y;Li D;Zhang J;Ju Z;Chen CS;Chen J;Zhang Y;He J
通讯作者：
He J